Amphastar pharmaceuticals reports financial results for the three months and full-year ended december 31, 2023

Reports net revenues of $178.1 million for the three months ended december 31, 2023 rancho cucamonga, ca / accesswire / february 28, 2024 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months and full-year ended december 31, 2023. fourth quarter highlights net revenues of $178.1 million for the fourth quarter gaap net income of $36.2 million, or $0.68 per share, for the fourth quarter adjusted non-gaap net income of $46.9 million, or $0.88 per share, for the fourth quarter full-year highlights net revenues of $644.4 million for the fiscal year gaap net income of $137.5 million, or $2.60 per share, for the fiscal year adjusted non-gaap net income of $175.7 million, or $3.32 per share, for the fiscal year dr. jack zhang, amphastar's president and chief executive officer, commented: "we enter 2024 with strong momentum.
AMPH Ratings Summary
AMPH Quant Ranking